Whitepaper: Why BioPharma Lifecycle Management?
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.
The effect of various ion pairing reagents (amines and acidic counterions) on the LC/UV and LC/MS analysis of oligonucleotides (ONs) has been studied.
21 January 2021 | By Yokogawa Life Innovations
Watch our on-demand webinar and learn how image-based phenotypic screening relies on extraction of multivariate information from cells cultured in a large number of screened conditions. In this webinar, we explore the application of complex and biologically relevant model systems for drug screening, such as small intestinal organoids.
This tissue-specific handbook brings you key publications, in-house protocols and troubleshooting recommendations for your organoid cell culture.
15 January 2021 | By Horizon Discovery
Watch our on-demand webinar where we discuss how CRISPR screening is proving to be a robust platform for the identification and validation of new biological targets for disease treatment. It is hoped that CRISPR screens will accelerate drug development by providing more robust targets for validation than siRNA screens, for…
According to a Public Health England study, prior SARS-CoV-2 infection provides 83 percent protection against reinfection but may not stop individuals spreading COVID-19.
Remdesivir is being prescribed under FDA emergency use authorisation as a treatment for patients with COVID-19.
LifeArc and the Medical Research Council have funded a new drug screening facility that will be established to accelerate COVID-19 drug discovery.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.